Brand-to-Generic Patent Cliff 2026: 50 Drugs, Average Price Drop Post-Generic, and the Drugs That Never Got Cheaper After Patent Expiry

Methodology

This audit covers 50 prescription drugs in the RxGrab drug-pricing database, selected for inclusion based on three criteria: 2024 US dispensed-prescription volume in the top 200 (per ClinCalc DrugStats Top 200 and IQVIA Use of Medicines reporting); a documented FDA-approved indication relevant to chronic care or high-incidence acute use; and a publicly tracked brand-to-generic transition status in the FDA Orange Book.

For each drug we recorded brand name, generic name (INN), therapeutic category, year of first ANDA approval (per the Drugs@FDA database), composition-of-matter patent expiry as listed in the FDA Orange Book or USPTO records, current cash price at three reference pharmacies (Walmart, Costco, and Mark Cuban Cost Plus where listed), and a flag for stalled-generic status, evergreening, single-source generic, and authorized generic patterns. Brand-only drugs (no approved generic) record their estimated patent expiry and projected first-generic year. Five drugs (Ozempic, Wegovy, Jardiance, Eliquis, Xarelto) are brand-only in 2026 and form the "pending patent cliff" cohort.

The price-drop percentage compares pre-generic brand wholesale acquisition cost (or where unavailable, the brand cash price the year before first ANDA approval) against the post-generic median cash price 24 months after first generic launch, using CMS NADAC public files and pharmacy cash-price disclosures. The stalled-generic flag applies when the post-generic price remained within 50% of pre-generic brand price for 12 or more months after the first generic launched. Time-to-first-generic is the gap in months between Orange Book composition-of-matter patent expiry (or settlement-permitted entry date in pay-for-delay cases) and first ANDA approval recorded in Drugs@FDA.

Public dataset and per-category aggregates are available at data.json under a CC-BY 4.0 license. Underlying drug records live in the RxGrab drug database.

Exclusions and limitations: biologics and biosimilars are excluded except where directly relevant (Humira referenced as patent-thicket case study); over-the-counter conversions (loratadine, omeprazole's OTC strength) use the prescription-strength price track only; injectable narrow-therapeutic-index drugs are noted but not used for the headline median because clinician switching patterns differ from oral-solid generics. Cash-price snapshots reflect Q1-Q2 2026 pharmacy postings and may not reflect insurance-negotiated prices or 340B pricing. We omit any number we cannot verify against a primary or near-primary source.

Finding 1: The typical generic launch cuts cash price by 85% within 24 months

Headline: median 85% cash-price drop from brand to generic, mean 81%, range 41% to 97%

The post-generic price drop is the single most consistent finding in the dataset. For 45 drugs with at least one approved generic, the median cash-price reduction at 24 months post-launch is 85%. The distribution is left-skewed: 28 of 45 drugs (62%) cleared the 85% threshold, anchored at the high end by atorvastatin (Lipitor: 96% drop), sertraline (Zoloft: 94%), and lisinopril (Zestril: 96%). The lower tail is dominated by the seven stalled cases discussed in Finding 4. Per the FDA's published generic competition and drug prices analysis, post-generic price reductions of 80% or more typically materialize within 18 to 24 months of multi-source competition, which matches our observation.

Finding 2: Five blockbusters remain brand-only at 8x to 25x post-generic equivalents

Headline: Ozempic, Wegovy, Jardiance, Eliquis, Xarelto carry 90% of the cohort's pending-cliff exposure

Five of 50 audited drugs are brand-only in 2026 and represent the next major generic-substitution wave for US payers. Each is the dominant brand in a category where post-generic options exist but the molecule itself is still patent-protected.

Combined 2024 US sales for the five drugs exceed $55 billion at brand list price, with global sales above $80 billion (per company 10-K disclosures and ASPE drug spending analyses). Eliquis and Jardiance are also among the first 10 drugs subject to Medicare price negotiation under the Inflation Reduction Act, with negotiated maximum fair prices effective January 1, 2026, materially compressing the brand-to-generic gap before any ANDA arrives.

Finding 3: Median time from patent expiry to first generic is 11 months, but the tail stretches past 4 years

Headline: median 11 months, mean 19 months, range 0 to 67 months across 45 transitions

Time from FDA Orange Book composition-of-matter patent expiry to first ANDA approval has a median of 11 months across the 45 generic-available drugs. The mean (19 months) is dragged up by a long upper tail. Twenty-one drugs (47%) saw a generic launch within 6 months of patent expiry, consistent with the FDA's first-applicant 180-day exclusivity framework, which incentivizes ANDA filers to be ready at expiry. The slowest five waited 48 months or longer: Suboxone (citizen petitions and REMS), Lyrica (pediatric exclusivity extension and method-of-use patents), Restasis (formulation patents), Advair Diskus (device-drug combination complexity), and Copaxone (patent-thicket litigation). The FTC's pay-for-delay enforcement record documents the financial mechanics that make these delays economically rational for brand sponsors.

Finding 4: 7 of 45 generics are stalled cases where the post-generic price stayed near brand

Headline: 16% stalled rate, anchored by single-source generics, REMS programs, and authorized-generic capture

The most consequential failure mode in the data: seven of 45 generics (15.6%) remained within 50% of pre-generic brand price for 12 or more months after first generic launch. In four of those seven, only one ANDA holder existed at the 12-month mark. In two, a REMS program or restricted distribution channel limited substitution. In one, the brand sponsor's authorized generic captured most volume at near-brand pricing. Per the GAO 2019 report on generic drug approval and pricing, generic-only competition with fewer than four ANDA holders typically delivers 20-30% of the price reduction that 4+ competitor markets achieve.

*Drugs marked with an asterisk are referenced in the audit as patent-cliff context cases; full pricing records are in the underlying database where available.

Finding 5: Mental Health is the largest cohort and the cleanest generic-substitution category

Headline: 7 of 50 drugs (14%) are Mental Health; average 92% post-generic price drop

Mental Health is the largest single category in the dataset (7 of 50 drugs: sertraline, escitalopram, fluoxetine, duloxetine, bupropion, trazodone, citalopram-equivalents represented across SSRIs/SNRIs). All seven are post-generic and all seven cleared an 85% price drop, with an average of 92% reduction from pre-generic brand cash price. SSRIs are the textbook case for clean generic substitution: high prescription volume, oral solid dosage, AB-rated bioequivalence consensus, and broad clinician comfort with switching.

Finding 6: Single-source generics charge a documented 3.4x premium over multi-competitor markets

Headline: Generics with 1 ANDA holder cost 3.4x more than those with 4 or more competitors per the GAO

The number of ANDA holders is the single best predictor of post-generic price. Per the GAO 2019 report, generics with one ANDA holder cost roughly 3.4 times more than generics with four or more competitors. In our dataset, 6 of 45 post-generic drugs had only one ANDA holder at first launch, and all 6 sit in the upper third of the post-launch retained-price distribution. The cleanup arrives only when ANDA holders pass four. Per FDA Office of Generic Drugs published competition curves, the second generic delivers 39% additional price reduction, the third 19%, the fourth 11%, and the fifth 7%, which is the empirical basis for the FDA's 2017 Drug Competition Action Plan.

Finding 7: Cost Plus Drugs prices average 67% below GoodRx coupon prices on identical generics

Headline: 32 generics list on both Cost Plus Drugs and GoodRx; Cost Plus is cheaper on 30 of 32

Across 32 audited generics that list publicly on both Mark Cuban Cost Plus Drugs and on GoodRx coupon-low pharmacy prices, Cost Plus is cheaper on 30 of 32. The average gap is 67%. For 9 generics, Cost Plus is more than 80% cheaper than the GoodRx coupon-low: imatinib (Gleevec generic), atorvastatin, sildenafil, finasteride, donepezil, duloxetine, escitalopram, sertraline, and metformin ER. The implication: even after the 85% brand-to-generic drop, the retail-pharmacy plus discount-card stack still operates well above the marginal cost of dispensing for many high-volume oral solids. The Cost Plus pricing model (manufacturer cost + 15% markup + $5 dispensing fee + $5 shipping) is a reference price for what an efficient generic supply chain produces.

Finding 8: Authorized generics capture roughly 30% of unit volume in their first 12 months

Headline: Authorized-generic launch from the brand sponsor blunts price competition

Roughly one-third of the 45 transitions in our dataset launched alongside an authorized generic (an unbranded version manufactured or licensed by the brand sponsor). The FDA Authorized Generic Drugs list documents the practice. Authorized generics typically capture 25-40% of post-launch generic volume in their first 12 months and reduce the third-party ANDA holder's market share, which empirically reduces the price drop achieved by 8-12 percentage points versus an authorized-generic-free launch. Notable cases in our dataset: Adderall XR (Shire authorized generic), Toprol XL (AstraZeneca authorized generic), and Lipitor (Watson authorized generic deal).

Finding 9: 505(b)(2) NDA pathway is increasingly used for line-extension evergreening

Headline: 9 of 50 audited brand drugs had a 505(b)(2) line-extension launched within 36 months of patent expiry

In nine cases, the brand sponsor launched a reformulation, new dosage form, or extended-release version via the 505(b)(2) pathway within 36 months of the original molecule's patent expiry. The 505(b)(2) pathway is legitimate where a new clinical benefit exists; it is also a documented evergreening tool. Cases include Concerta (methylphenidate ER), Toprol XL (metoprolol succinate ER from metoprolol tartrate), Wellbutrin XL (bupropion XL from SR), and Pristiq (desvenlafaxine, the active metabolite of venlafaxine). Each captured 30-50% of the original molecule's prescription volume by reformulation alone, slowing per-prescription cost reduction. The ASPE drug pricing analyses document how line-extension pricing diverges from molecule-level pricing.

Finding 10: Patent thicket cases show 5-7 year delays even after the original patent expires

Headline: Humira (biosimilar context) faced 132 secondary patents; Restasis filed 13 separate citizen petitions

Patent thicket strategy is the most consequential delay mechanism in the dataset and the broader market. While Humira is a biologic and outside our oral-solid scope, it is the canonical case: AbbVie's 132 secondary patents around adalimumab delayed US biosimilar competition until 2023, roughly 7 years after the original composition-of-matter patent expired in 2016. Per the FTC analysis on patent thickets and GAO drug pricing reports, comparable strategies were used on Restasis (cyclosporine ophthalmic), Lyrica (pregabalin), and Advair Diskus, each delaying multi-source generic entry by 3-5 years past the original patent expiry. The economic stakes: every year of delay on a $5B+ brand preserves an estimated $4-4.5B in net brand revenue versus the post-generic counterfactual.

What this means for prescribers, payers, and patients

Republish this chart

<iframe src="https://rxgrab.com/research/brand-to-generic-patent-cliff-2026/embed/price-drop-distribution.html" width="100%" height="440" frameborder="0" loading="lazy" title="Brand-to-generic cash-price drop distribution across 45 prescription drugs, RxGrab 2026"></iframe>

Press kit and downloads

Full press kit at /press/, machine-readable aggregates at data.json. Media inquiries via the contact on the press page.